The report provides a detailed analysis essential for establishing an Emtricitabine production plant. It encompasses all critical aspects necessary for Emtricitabine production, including the cost of Emtricitabine production, Emtricitabine plant cost, Emtricitabine production costs, and the overall Emtricitabine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Emtricitabine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Emtricitabine is an FDA-approved drug mainly known for its potent antiviral activity. The drug is widely utilized for the treatment and prevention of HIV infection. Moreover, it is also used as an oral drug for the treatment of chronic hepatitis B. It is often used for the treatment of HIV-1 and HIV-2 virus infection. Additionally, it is also employed in combination therapy with other antiviral drugs for the treatment of HIV infection.
The market for Emtricitabine is primarily led by its role as a Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor that serves as an antiviral drug, which significantly boosts its demand in the medical industry. Moreover, its usage as a potent oral drug for its clinical activity against hepatitis B virus (HBV) further enhances its demand in the pharmaceutical and healthcare industries. Additionally, its application for the treatment of HIV infection as a combination therapy with other antiviral agents due to its strong antiviral activity with good safety notably fuels its market growth. Overall, the availability of raw materials (2,5-dihydroxy-1,4-dithiane, etc.), cost and pricing, adherence to healthcare regulations, quality standards, distribution (including trading and shipping), logistics, safety standards, etc., are some of the major factors that influence industrial Emtricitabine procurement worldwide.
Raw Material for Emtricitabine Production
According to the Emtricitabine production plant project report, the major raw materials for Emtricitabine production include 2,5-Dihydroxy-1,4-dithiane and Glyoxylic Acid.
Production Process of Emtricitabine
The extensive Emtricitabine production cost report consists of the following industrial production process:
- Production from Glyoxylic Acid: This method of production involves a highly diastereoselective process to produce Emtricitabine as the desired product. The process is initiated by the reaction of 2,5-dihydroxy-1,4-dithiane with glyoxylic acid to synthesize trans-hydroxy acid. Further, the obtained compound is reacted with menthol in the presence of DCC/DMAP to form a diastereomeric mixture of cis and trans-esters, respectively. Then, the mixture is further reacted with presilylated fluorocytosine, followed by treatment with lithium aluminum hydride, which results in the formation of Emtricitabine as the final product.
Emtricitabine is a chemical organofluorine compound that serves as a drug for the treatment of HIV-1 infection. It is a fluoro derivative of thiacytidine. The molecular formula of the compound is C8H10FN3O3S, and its molecular weight is 247.25 g/mol. Moreover, the compound is broadly marketed under the trade name Emtriva. The melting point of the compound is 136-140°C, and the boiling point of the compound is 443.3 °C. Its density is around 1.82g/cm3, and it is stored in a dark place and an inert atmosphere at 2-8°C. Additionally, the value of its dissociation constant (pka) is 13.83, and it is does not dissolve in water but is slightly soluble in Chloroform.